Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

ASCVD Risk in South Asians Far Exceeds Forecasts by Common Scores

News Daily News

ASCVD Risk in South Asians Far Exceeds Forecasts by Common Scores

July 12, 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

News Conference News ACC 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

Michael O'Riordan

May 15, 2021

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

News Daily News

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

Michael O'Riordan

January 14, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.